These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34308395)

  • 1. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19.
    Lim WW; Mak L; Leung GM; Cowling BJ; Peiris M
    Lancet Microbe; 2021 Sep; 2(9):e423. PubMed ID: 34308395
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021.
    Cui X; Wang P; Wei Z
    Drug Discov Ther; 2021 Sep; 15(4):222-224. PubMed ID: 34275974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
    Larkin HD
    JAMA; 2022 Jun; 327(23):2280. PubMed ID: 35727270
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
    Martin P; Clarke C
    EBioMedicine; 2021 Sep; 71():103567. PubMed ID: 34454401
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors.
    Ugurlu S; Akcin R; Ayla AY; Kocazeybek B; Oztas M; Can G; Mustafayeva L; Saltoglu N; Yilmaz B; Ozdogan H
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI194-SI196. PubMed ID: 35258567
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
    Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E
    Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of SARS-CoV-2 variants on IBD management.
    Segal JP; Kumar A; Raine T; Lamb CA; Brookes MJ
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):343-344. PubMed ID: 33711289
    [No Abstract]   [Full Text] [Related]  

  • 11. The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year.
    Zhang Z; Ju B; Zhou X; Cheng L; Wang H; Liao X; Wang M; Wei L; Song S; Zhou B; Ma Z; Guo H; Ge X
    Emerg Microbes Infect; 2022 Dec; 11(1):753-756. PubMed ID: 35184681
    [No Abstract]   [Full Text] [Related]  

  • 12. Africa needs more genome sequencing to tackle new variants of SARS-CoV-2.
    Otu A; Agogo E; Ebenso B
    Nat Med; 2021 May; 27(5):744-745. PubMed ID: 33828291
    [No Abstract]   [Full Text] [Related]  

  • 13. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Vaccines.
    Creech CB; Walker SC; Samuels RJ
    JAMA; 2021 Apr; 325(13):1318-1320. PubMed ID: 33635317
    [No Abstract]   [Full Text] [Related]  

  • 15. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.
    Sapkal GN; Yadav PD; Ella R; Deshpande GR; Sahay RR; Gupta N; Vadrevu KM; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33772577
    [No Abstract]   [Full Text] [Related]  

  • 16. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients.
    Deng Y; Li Y; Yang R; Tan W
    Cell Mol Immunol; 2021 Aug; 18(8):2040-2041. PubMed ID: 34267334
    [No Abstract]   [Full Text] [Related]  

  • 17. Messenger RNA vaccines against SARS-CoV-2.
    Topol EJ
    Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Audio Interview: How Well Are Covid-19 Vaccines Working?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Jul; 385(2):e15. PubMed ID: 34233102
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
    Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
    J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
    [No Abstract]   [Full Text] [Related]  

  • 20. A network analysis of COVID-19 mRNA vaccine patents.
    Gaviria M; Kilic B
    Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.